Novartis has entered into a Memorandum of Understanding to acquire Advanced Accelerator Applications (AAA), a nuclear medicine theragnostics company, in a transaction valued at approximately $3.9 billion. The proposed transaction has been approved by the AAA board of directors and Novartis, and is subject to customary transactional regulatory approvals.   Mr. Stefano Buono, chief executive officer of AAA, said, “It is with great satisfaction that we announce this proposed transaction with Nova...